Notification/Circular No.: G.S.R. 955(E) dated October 28, 2026
Applicable Act/Rule: Drugs and Cosmetics Act, 1940; Drugs Rules, 1945; Schedule M; Schedule U; Schedule F (Part XII-C)
Applicable Section/Rule: Section 33(1) of the Drugs and Cosmetics Act, 1940; insertion of rule 68C; amendments to rules 74(d), 74A(f), 74B(3), 78(c)(i), 78A(3); proviso to rule 122G(1) (Form 28E); amendments to Schedule F Part XII-C and Schedule U
The Ministry of Health and Family Welfare has issued G.S.R. 955(E) publishing the draft Drugs (Amendment) Rules, 2026 under section 33(1) of the Drugs and Cosmetics Act, 1940. The draft addresses authorization for batch release and maintenance of batch release records in compliance with Schedule M and Schedule U.
The draft proposes a new rule 68C requiring every applicant for a licence under the relevant part to authorize a person, with appropriate qualification and experience, for batch release in compliance with Schedule M. It mandates that records for batch release of each batch of drugs manufactured must be prepared as per the particulars set out in Schedule U. A similar proviso is proposed in rule 122G(1) for applicants under Form 28E.
To embed this requirement across the licensing framework, the draft amends rule 74(d) to add “and records of batch release” after “manufacture”, and amends rules 74A(f), 74B(3) and 78A(3) to state that the licensee shall also keep batch release records for each batch as per Schedule U. Rule 78(c)(i) is amended to add “and batch release” after “manufacture”. In Schedule F, Part XII-C (requirements for the manufacture of blood products), in paragraph J on Records, the draft adds that licensees shall also keep records of batch release as per the particulars given in Schedule U for each batch manufactured.
The draft also supplements Schedule U to specify the details that must be included in a Batch Release Certificate (Quality Control Certificate). At a minimum, the certificate must capture the certificate number; product name and dosage form; composition and the quantity of each constituent per unit dose; licence number and date of issue; batch or lot number and size; dates of manufacture and expiry or retest; names and addresses of all manufacturing and testing sites; marketer details; details of qualified equipment used; environmental monitoring records; batch manufacturing and packing records; line clearances; in‑process quality control test reports; protocols of tests applied; certificate of analysis; analytical results; and analytical report number. It must include a Certificate of Conformity in which an authorised person certifies, after reviewing the supporting documents, that the batch has been manufactured (including packing) and tested at the stated site(s) in compliance with the GMP requirements under the Drugs Rules, 1945, with the date and the authorised person’s signature.
Objections and suggestions will be considered by the Central Government if received within thirty days from the date on which copies of the Gazette containing the draft rules are made available to the public. Submissions may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall- C Wing, First Floor, Kartavya Bhawan-1, New Delhi, 110001, or emailed to drugsdiv-mohfw@gov.in. The draft rules state that they shall come into force after three months from their publication in the Official Gazette.
Link: https://egazette.gov.in/WriteReadData/2026/277607.pdf
Disclaimer: The information contained in this Article is intended solely for personal non-commercial use of the user who accepts full responsibility of its use. The information in the article is general in nature and should not be considered to be legal, tax, accounting, consulting or any other professional advice. We make no representation or warranty of any kind, express or implied regarding the accuracy, adequacy, reliability or completeness of any information on our page/article.
To stay updated Subscribe to our newsletter today
Explore other Legal updates on the Corplico and follow us on LinkedIn to stay updated